Head Trauma
RSSArticles
-
Treating Multiple Sclerosis: Why Wait?
Glatiramer acetate significantly delayed the onset of clinically definite multiple sclerosis (MS) in patients having a clinically isolated event and brain lesions consistent with MS. -
Clinical Briefs in Primary Care Supplement
-
What Is Frontotemporal Lobar Degeneration? New Clues Emerge
Two studies have identified a novel inclusion found in a subset of FTLD brains and categorize the clinical entity of the behavioral variant of FTLD, based on anatomical patterns. -
Pharmacokinetics of IV Immunoglobulins and Outcome in GBS
Fixed dose of IVIg may not be effective in all patients with GBS. -
Neuropathy in Liver Failure
Neuropathy occurs with a high frequency in patients with end-stage liver disease, but rarely causes disability. -
Ocular Myasthenia in Seniors: A Case for Treatment
Immunomodulatory therapy reduces the rate of conversion to generalized myasthenia gravis in seniors with pure ocular myasthenia. -
Non-Oculopharyngeal Involvement in OPMD
Oculopharyngeal muscular dystrophy is a rare, autosomal dominant neuromuscular disorder that has recently been genetically defined and may be treatable with myoblast transplantation. -
Baseline Impairments and Decline in Cognition in Early Parkinson’s Disease
The Montreal Cognitive Assessment and Mini-Mental Status Exam demonstrated baseline deficits in early Parkinsons disease. -
Stroke Alert: A Review of Current Clinical Stroke Literature
Blood Pressure Variability May Predict Poor Outcome After Intracerebral Hemorrhage -
B-lymphocyte Targeted Therapies for MS — Paradoxical Effect of Atacicept
A Phase 2 trial of atacicept, a humanized recombinant protein that suppresses B cell function, demonstrated a negative impact on clinical disease activity in relapsing-remitting multiple sclerosis.